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We read with great interest the paper by Akbari and 
colleagues [1] in a recent issue of Breast Cancer Research. 
Th   e authors reported on the absence of RAD51C muta-
tions in 454 patients with BRCA1/2-negative familial 
breast cancer/ovarian cancer (BC/OC). In the initial 
report by Meindl and colleagues [2], RAD51C mutations 
were identiﬁ  ed in 6 out of 480 patients with BRCA1/2-
negative familial BC/OC. Interestingly, on the basis of 
histopathologic features, including intermediate grade 
(G2), estrogen receptor-positive (ER+), progesterone 
receptor-positive (PR+), and HER2-negative (HER2−) 
expression,  RAD51C-associated BCs were found to be 
similar to BRCA2-associated BCs [2]. BRCA2 is known to 
play a signiﬁ  cant role in male BC (MBC); however, no 
occur  rence of MBC was observed in the six RAD51C
families described [2].
To investigate the role of RAD51C in MBC, we screened 
for RAD51C mutations in 97 MBC patients selected from 
our population-based series of 126 cases because they 
were previously found negative for BRCA1/2,  CHEK2, 
PALB2, and BRIP1 mutations [3,4]. Notably, 25.8% of cases 
showed a positive ﬁ  rst-degree family history of BC or OC 
or both. Th  e majority of MBCs were invasive ductal 
carcinomas (74.5%), G2 (53.5%), ER+ (90.7%), PR+ (82.6%), 
or HER2− (85.4%). Overall, 66% of the MBCs showed an 
ER+/PR+/HER2− phenotype. All patients provided in-
formed consent to the study. We carried out mutation 
screening of the nine exons and intron/exon boundaries of 
RAD51C by high resolution melting (HRM) analysis, a 
rapid closed-tube mutation scanning method with high 
sensitivity and speci  ﬁ   city. Cases displaying abnormal 
proﬁ  les were evaluated by direct sequencing. Primers are 
available upon request.
We found no truncating RAD51C mutations. We 
identi ﬁ  ed a novel intronic variant, IVS3 c.738-16G>T, in 
1 out of 97 MBCs (1%). By in silico analysis, performed 
with Splice Site Prediction (Berkeley Drosophila Genome 
Project, Lawrence Berkeley National Labora  tory, Berkeley, 
CA, USA) and NetGene 2 Server software (Center for 
Biological Sequence Analysis, Tech  nical University of 
Denmark, Lyngby, Denmark), the IVS3 c.738-16G>T
variant is predicted not to aﬀ  ect splicing. Th  is variant 
was also identiﬁ   ed in 2 out of 173 (1.2%) population 
controls examined. We also found a neutral polymorphic 
intronic variant, IVS6 c.904+34T>C (rs28363318), in 16 
out of 97 (16.5%) MBCs.
Overall, our results, which are based on a relatively 
large MBC series, are consistent with the ﬁ  ndings  by 
Akbari and colleagues [1] and with data on 92 patients 
with hereditary gynecological cancer in which no 
deleterious  RAD51C mutations were identiﬁ  ed [5] and 
would suggest that the impact of RAD51C mutations on 
BC predisposition might be more limited than initially 
reported. In conclusion, we found no evidence that 
RAD51C  mutations may contribute to MBC suscep-
tibility. Further studies on larger MBC series are needed 
to conﬁ  rm our ﬁ  ndings.
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